Abstract
Placental pathology can be a cause of early severe FGR leading to perinatal morbidity and mortality with repercussions in future pregnancies. A diagnosis of a placental lesion on ultrasound should have a detailed clinical and histopathological correlation for better management in next pregnancy. We present a case report of “placental massive perivillous fibrinoid degeneration/maternal floor infarction (MPFD)” with very large avascular placenta. This can lead to fetal growth restriction (FGR) and other complications for the fetus. It is also known to be associated with antiphospholipid syndrome. Management with low dose aspirin and low molecular weight heparin achieves good results.
References
Al Sahan N, Gynspan D, Von Dadelszen P, Guslin A. Maternal floor infarction – Management of an unrecognised pathology. J Obst Gynecol Res. 2014;40:293–6.
Benirschke K. Examination of placenta. Obst Gynecol. 1961;18:309–33.
Chen A, Roberts DJ. Placental pathologic lesions with a significant recurrence risk, What not to miss. J Pathol Microbiol Immunol. 2017;126:589–601.
Kulkarni AD, Palaniappan N, Evans MJ. Placental pathology and stillbirth, A review of the literature and guidelines for the less experienced. J Fetal Med. 2017;4:177–85.
Dashe JS, Hoffman BL USG evaluation of the placenta, membranes and umbilical cord. Callen’s USG in OBGY, 6th edition 2017. P. 674–683.
Romero R, Whitten A, Korzeniewski SJ, et al. Maternal floor infarction/massive perivillous fibrin deposition: a manifestation of maternal antifetal rejection? Am J Reprod Immunol. 2013;70:285–98.
Andres RL, Kuyper W, Reshik R, Piacquadio KM, Benirschke K. The association of maternal floor infarction of the placenta with adverse perinatal outcome. Am J Obstet Gynecol. 1990;163:935–8.
Katzman PJ, Genest DR. maternal floor infarction and massive perivillous fibrinoid degeneration—histological definitions, association with IUGR and risk of recurrence. Paed Dev Pathol. 2002;5:159–64.
Gogia N, Machin GA. Maternal thrombophilias are associated with specific placental lesions. Pediatric Dev Pathol. 2008;11:424–9.
Bane AL, Gillan JE. Massive perivillous fibrin deposition causing recurrent placental failure. BJOG. 2003;110:292–5.
Benirschke K, Driscoll SG. maternal floor infarction—the Pathology of human placenta. New York: Springer Verlag; 1967. p. 328–30.
Sebire NJ, Backos M, Goldin RD, et al. Placental massive perivillous fibrinoid degeneration associated with antiphospholipid syndrome. BJOG. 2002;109:570–3.
Redine RW, Jiang JG, Shah D. Discordancy for maternal floor infarction in dizygotic twin placentas. Hum Pathol. 2003;34:822–4.
Makino A, Suzuki Y, Yamamoto T, Sato T, Kojima K. Use of aspirin and LMWH to prevent recurrence of maternal floor infarction in women without evidence of antiphospholipid anibody syndrome. Fetal Diagn Ther. 2004;19:261–5.
Morreti SAF, Gruslin A, Grynspan D. Recurrent massive perivillous fibrinoid degeneration and chronic intervillositis treated with heparin and Intravenous immunoglobulin- a case report. J OBGY Can. 2017;39(8):676–81.
Kutteh WH, Hinote C. Antiphospholipid antibody syndrome. Obstet Gynecol Clin N Am. 2014;41:113–32.
Chaiworapongsa T, Romero R, Korzeniewski S, Chaemsaithong P, Andrade EH. Provastatin to prevent recurrent fetal death in MPFD. J Matern Fetal Neonatal Med. 2016;29(6):855–62.
Edison RJ, Muenke M. Mechanistic and epidemiologic consideration in the evaluation of adverse birth outcome following gestational exposure to statins. Am J Med Genet. 2004;131:1287–98.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Panat, V.M. Massive Perivillous Fibrinoid Degeneration of Placenta/ Maternal Floor Infarct: A Case Report. J. Fetal Med. 8, 81–84 (2021). https://doi.org/10.1007/s40556-021-00290-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40556-021-00290-x